13F Holdings
中文EN

MBOT Microbot Medical Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883975 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-26.3%
ROA-24.8%
ROIC (approx.)-25.2%
Asset turnover—

Leverage & solvency

Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$6.28M$6.63M$5.72M$7.74M$6.15M
SG&A expense$8.46M$5.00M$4.13M$5.54M$5.20M
Operating income-$14.74M-$11.62M-$9.86M-$13.28M-$11.36M
Net income-$13.14M-$11.44M-$10.74M-$13.17M-$11.31M
EBITDA-$14.70M-$11.53M-$9.75M-$13.18M-$11.28M
EPS (basic)-0.29-0.73-1.05-1.81-1.59
EPS (diluted)-0.29-0.73-1.05-1.81-1.59
Weighted avg. shares (diluted)45.79M15.64M10.20M7.26M7.11M
Balance sheet
Cash & equivalents$3.91M$3.11M$2.47M$2.44M$13.49M
Short-term investments$74.68M$2.36M$3.92M$5.76M$2.00M
Inventory$584,000————
Current assets$79.82M$5.82M$7.92M$8.81M$15.88M
PP&E, net$93,000$80,000$146,000$221,000$244,000
Total assets$81.54M$6.03M$8.33M$9.54M$16.77M
Current liabilities$3.42M$2.46M$3.79M$2.07M$1.98M
Total liabilities$3.99M$2.50M$3.83M$2.25M$2.39M
Shareholders' equity$77.55M$3.53M$4.50M$7.29M$14.38M
Shares outstanding67.16M19.40M11.71M7.89M7.11M
Cash flow statement
Operating cash flow-$13.05M-$8.83M-$8.53M-$11.55M-$9.35M
Capital expenditure$60,000$25,000$33,000$84,000$69,000
Free cash flow-$13.11M-$8.85M-$8.57M-$11.63M-$9.42M
Investing cash flow-$72.38M$1.54M$1.97M-$3.84M$3.20M
Financing cash flow$86.24M$7.94M$6.56M$4.32M—
Depreciation & amortization$47,000$91,000$106,000$102,000$76,000
Stock-based compensation$1.06M$1.35M$1.39M$1.75M$1.39M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.